Fulvestrant (Faslodex®) - Outcomes of the Expanded Access Programme (EAP) with ZD9238 (Fulvestrant) in Germany for postmenopausal patients with hormone sensitive, metastatic breast cancer after progression under hormone therapy

Authors
Publication date
20 March 2006
Publisher
German Medical Science; Düsseldorf, Köln

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    German Medical Science

    redirect
    oaioai:oai-gms.dimdi.de:GM06dkk15...
    Last time updated on 09/07/2019